Role of Pertussis Booster Vaccination in EU Immunisation Strategies

Booster vaccination plays a central role in pertussis prevention across the European Union. While primary vaccination provides early protection, immunity wanes over time, underscoring the importance of booster doses for adolescents, adults, and individuals at heightened risk. BioNet’s pertussis-only vaccine has been authorised to support these booster strategies.

Immunisation policies across the EU are determined at the national level, shaped by each Member State’s epidemiological trends, healthcare priorities, and population needs. Within this framework, booster programmes aim to reduce symptomatic disease and curb transmission, particularly to vulnerable young infants who cannot yet be fully protected by primary vaccination alone.

The availability of a standalone pertussis booster offers national authorities a more targeted option, especially where repeated pertussis boosters are recommended without the need for additional tetanus or diphtheria components.

During its evaluation, the CHMP assessed how the pertussis-only vaccine integrates within existing vaccination programmes, confirming that it meets EU standards for quality, safety, and efficacy across its approved indications.

#pertussis-only #Vaccines #EMA #EU #booster #PTgen #PublicHealth #Pertussis #Biotechnology

Read the full news: VacPertagen Receives EU Approval